Study design
This was a three‐arm, double‐blind, parallel‐group randomized active‐controlled trial. Ethical approval was provided by the ethics board at Damascus University, and It was conducted according to Helniski Declaration 2013 and to CONSORT statement. This study took place between October 13, 2022, and February 15, 2023, at Damascus University. The current clinical trial was registered and approved by Australian New Zealand Clinical Trials Registry (ACTRN12623000524695).